Azvudine efficacy in reducing mortality in COVID-19 patients

{ 'indexed': { 'date-parts': [[2024, 12, 27]], 'date-time': '2024-12-27T05:18:17Z', 'timestamp': 1735276697716, 'version': '3.32.0'}, 'reference-count': 25, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2024, 12, 26]], 'date-time': '2024-12-26T00:00:00Z', 'timestamp': 1735171200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0'}, { 'start': { 'date-parts': [[2024, 12, 26]], 'date-time': '2024-12-26T00:00:00Z', 'timestamp': 1735171200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0'}], 'funder': [ {'name': 'Health Commission of Jiangxi Province,China江西省卫生健康委员会', 'award': ['202310802']}, { 'DOI': '10.13039/501100004479', 'name': 'Natural Science Foundation of Jiangxi Province', 'doi-asserted-by': 'publisher', 'award': ['82060363'], 'id': [{'id': '10.13039/501100004479', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'name': 'Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular ' 'Diseases,Ministry of Education', 'award': ['XN202023']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'DOI': '10.1186/s40001-024-02220-9', 'type': 'journal-article', 'created': { 'date-parts': [[2024, 12, 26]], 'date-time': '2024-12-26T08:39:39Z', 'timestamp': 1735202379000}, 'update-policy': 'https://doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Azvudine efficacy in reducing mortality in COVID-19 patients', 'prefix': '10.1186', 'volume': '29', 'author': [ {'given': 'Zhen', 'family': 'Zhong', 'sequence': 'first', 'affiliation': []}, {'given': 'Xiao-feng', 'family': 'Liu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xiao-zhong', 'family': 'Zhou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jia-ning', 'family': 'Zhong', 'sequence': 'additional', 'affiliation': []}, {'given': 'Li-cheng', 'family': 'Zhou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rong', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xian-fa', 'family': 'Liu', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2024, 12, 26]]}, 'reference': [ { 'issue': '5', 'key': '2220_CR1', 'doi-asserted-by': 'publisher', 'first-page': '474', 'DOI': '10.1056/NEJMc2206277', 'volume': '387', 'author': 'AM Morris', 'year': '2022', 'unstructured': 'Morris AM, Lee TC. Nirmatrelvir for nonhospitalized adults with ' 'Covid-19. N Engl J Med. 2022;387(5):474–5. ' 'https://doi.org/10.1056/NEJMc2206277.', 'journal-title': 'N Engl J Med'}, { 'issue': '10', 'key': '2220_CR2', 'doi-asserted-by': 'publisher', 'first-page': '1731', 'DOI': '10.3390/vaccines10101731', 'volume': '10', 'author': 'I Gentile', 'year': '2022', 'unstructured': 'Gentile I, et al. Nirmatrelvir/ritonavir and molnupiravir in the ' 'treatment of mild/moderate COVID-19: results of a real-life study. ' 'Vaccines. 2022;10(10):1731. https://doi.org/10.3390/vaccines10101731.', 'journal-title': 'Vaccines'}, { 'issue': '10359', 'key': '2220_CR3', 'doi-asserted-by': 'publisher', 'first-page': '1213', 'DOI': '10.1016/S0140-6736(22)01586-0', 'volume': '400', 'author': 'CKH Wong', 'year': '2022', 'unstructured': 'Wong CKH, et al. Real-world effectiveness of molnupiravir and ' 'nirmatrelvir plus ritonavir against mortality, hospitalisation, and ' 'in-hospital outcomes among community-dwelling, ambulatory patients with ' 'confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an ' 'observational study. Lancet (London, England). 2022;400(10359):1213–22. ' 'https://doi.org/10.1016/S0140-6736(22)01586-0.', 'journal-title': 'Lancet (London, England)'}, { 'key': '2220_CR4', 'doi-asserted-by': 'publisher', 'first-page': 'e074572', 'DOI': '10.1136/bmj-2022-074572', 'volume': '381', 'author': 'Y Xie', 'year': '2023', 'unstructured': 'Xie Y, et al. Molnupiravir and risk of post-acute sequelae of covid-19: ' 'cohort study. BMJ. 2023;381:e074572. ' 'https://doi.org/10.1136/bmj-2022-074572.', 'journal-title': 'BMJ'}, { 'issue': '1', 'key': '2220_CR5', 'doi-asserted-by': 'publisher', 'first-page': '414', 'DOI': '10.1038/s41392-021-00835-6', 'volume': '6', 'author': 'J-L Zhang', 'year': '2021', 'unstructured': 'Zhang J-L, et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug ' 'effective in treating COVID-19 patients. Signal Transduct Target Ther. ' '2021;6(1):414. https://doi.org/10.1038/s41392-021-00835-6.', 'journal-title': 'Signal Transduct Target Ther'}, { 'issue': '6', 'key': '2220_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1633', 'DOI': '10.1007/s15010-023-02028-5', 'volume': '51', 'author': 'P Bertuccio', 'year': '2023', 'unstructured': 'Bertuccio P, et al. The impact of early therapies for COVID-19 on death, ' 'hospitalization and persisting symptoms: a retrospective study. ' 'Infection. 2023;51(6):1633–44. ' 'https://doi.org/10.1007/s15010-023-02028-5.', 'journal-title': 'Infection'}, { 'issue': '5', 'key': '2220_CR7', 'doi-asserted-by': 'publisher', 'first-page': 'e2314393', 'DOI': '10.1001/jamanetworkopen.2023.14393', 'volume': '6', 'author': 'DTW Lui', 'year': '2023', 'unstructured': 'Lui DTW, et al. Analysis of all-cause hospitalization and death among ' 'nonhospitalized patients with type 2 diabetes and SARS-CoV-2 infection ' 'treated with molnupiravir or nirmatrelvir-ritonavir during the omicron ' 'wave in Hong Kong. JAMA Netw Open. 2023;6(5):e2314393. ' 'https://doi.org/10.1001/jamanetworkopen.2023.14393.', 'journal-title': 'JAMA Netw Open'}, { 'issue': '15', 'key': '2220_CR8', 'doi-asserted-by': 'publisher', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'volume': '386', 'author': 'J Hammond', 'year': '2022', 'unstructured': 'Hammond J, et al. Oral nirmatrelvir for high-risk, nonhospitalized ' 'adults with Covid-19. N Engl J Med. 2022;386(15):1397–408. ' 'https://doi.org/10.1056/NEJMoa2118542.', 'journal-title': 'N Engl J Med'}, { 'key': '2220_CR9', 'doi-asserted-by': 'publisher', 'first-page': '114367', 'DOI': '10.1016/j.biopha.2023.114367', 'volume': '162', 'author': 'SMR Hashemian', 'year': '2023', 'unstructured': 'Hashemian SMR, et al. Paxlovid (Nirmatrelvir/Ritonavir): a new approach ' 'to Covid-19 therapy? Biomed Pharmacother Biomedecine & Pharmacotherapie. ' '2023;162:114367. https://doi.org/10.1016/j.biopha.2023.114367.', 'journal-title': 'Biomed Pharmacother Biomedecine & Pharmacotherapie'}, { 'issue': '6', 'key': '2220_CR10', 'doi-asserted-by': 'publisher', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'volume': '386', 'author': 'A Jayk Bernal', 'year': '2022', 'unstructured': 'Jayk Bernal A, et al. Molnupiravir for oral treatment of covid-19 in ' 'nonhospitalized patients. N Engl J Med. 2022;386(6):509–20. ' 'https://doi.org/10.1056/NEJMoa2116044.', 'journal-title': 'N Engl J Med'}, { 'issue': '9', 'key': '2220_CR11', 'doi-asserted-by': 'publisher', 'first-page': '740', 'DOI': '10.1038/s41594-021-00651-0', 'volume': '28', 'author': 'F Kabinger', 'year': '2021', 'unstructured': 'Kabinger F, et al. Mechanism of molnupiravir-induced SARS-CoV-2 ' 'mutagenesis. Nat Struct Mol Biol. 2021;28(9):740–6. ' 'https://doi.org/10.1038/s41594-021-00651-0.', 'journal-title': 'Nat Struct Mol Biol'}, { 'issue': '3', 'key': '2220_CR12', 'doi-asserted-by': 'publisher', 'first-page': '415', 'DOI': '10.1093/infdis/jiab247', 'volume': '224', 'author': 'S Zhou', 'year': '2021', 'unstructured': 'Zhou S, et al. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 through lethal ' 'mutagenesis but is also mutagenic to Mammalian cells. J Infect Dis. ' '2021;224(3):415–9. https://doi.org/10.1093/infdis/jiab247.', 'journal-title': 'J Infect Dis'}, { 'issue': '1', 'key': '2220_CR13', 'doi-asserted-by': 'publisher', 'first-page': '236', 'DOI': '10.1038/s41392-020-00351-z', 'volume': '5', 'author': 'B Yu', 'year': '2020', 'unstructured': 'Yu B, Chang J. Azvudine (FNC): a promising clinical candidate for ' 'COVID-19 treatment. Signal Transduction Targeted Therapy. 2020;5(1):236. ' 'https://doi.org/10.1038/s41392-020-00351-z.', 'journal-title': 'Signal Transduction Targeted Therapy'}, { 'issue': '11', 'key': '2220_CR14', 'doi-asserted-by': 'publisher', 'first-page': '685', 'DOI': '10.1038/s41579-021-00630-8', 'volume': '19', 'author': 'H Yang', 'year': '2021', 'unstructured': 'Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for ' 'therapeutic development. Nat Rev Microbiol. 2021;19(11):685–700. ' 'https://doi.org/10.1038/s41579-021-00630-8.', 'journal-title': 'Nat Rev Microbiol'}, { 'issue': '19', 'key': '2220_CR15', 'doi-asserted-by': 'publisher', 'first-page': 'e2001435', 'DOI': '10.1002/advs.202001435', 'volume': '7', 'author': 'Z Ren', 'year': '2020', 'unstructured': 'Ren Z, et al. A Randomized, open-label, controlled clinical trial of ' 'azvudine tablets in the treatment of mild and common COVID-19, a pilot ' 'study. Adv Sci. 2020;7(19):e2001435. ' 'https://doi.org/10.1002/advs.202001435.', 'journal-title': 'Adv Sci'}, { 'issue': '1228548', 'key': '2220_CR16', 'doi-asserted-by': 'publisher', 'first-page': '24', 'DOI': '10.3389/fphar.2023.1228548', 'volume': '14', 'author': 'K-W Zhu', 'year': '2023', 'unstructured': 'Zhu K-W. Efficacy and safety evaluation of Azvudine in the prospective ' 'treatment of COVID-19 based on four phase III clinical trials. Front ' 'Pharmacol. 2023;14(1228548):24. ' 'https://doi.org/10.3389/fphar.2023.1228548.', 'journal-title': 'Front Pharmacol'}, { 'key': '2220_CR17', 'doi-asserted-by': 'publisher', 'first-page': '23974', 'DOI': '10.1038/s41598-024-74502-5', 'volume': '14', 'author': 'H Xie', 'year': '2024', 'unstructured': 'Xie H, Wang Y, Xu Y, et al. Effectiveness and safety of azvudine versus ' 'nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron ' 'strains: a retrospective study in Beijing. Sci Rep. 2024;14:23974. ' 'https://doi.org/10.1038/s41598-024-74502-5.', 'journal-title': 'Sci Rep'}, { 'key': '2220_CR18', 'doi-asserted-by': 'publisher', 'unstructured': 'National Health Commission of the People’s Republic of China. Diagnosis ' 'and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version ' '10). Chin J Clin Infect Dis. 2023; 16(01): 1–9. ' 'https://doi.org/10.3760/cma.j.issn.1674-2397.2023.01.001.', 'DOI': '10.3760/cma.j.issn.1674-2397.2023.01.001'}, { 'key': '2220_CR19', 'doi-asserted-by': 'publisher', 'first-page': '101981', 'DOI': '10.1016/j.eclinm.2023.101981', 'volume': '59', 'author': 'Y Sun', 'year': '2023', 'unstructured': 'Sun Y, et al. Oral Azvudine for hospitalised patients with COVID-19 and ' 'pre-existing conditions: a retrospective cohort study. ' 'EClinicalMedicine. 2023;59:101981. ' 'https://doi.org/10.1016/j.eclinm.2023.101981.', 'journal-title': 'EClinicalMedicine'}, { 'issue': '8', 'key': '2220_CR20', 'doi-asserted-by': 'publisher', 'first-page': '2087', 'DOI': '10.1007/s40121-023-00845-7', 'volume': '12', 'author': 'Q Zhao', 'year': '2023', 'unstructured': 'Zhao Q, et al. Is azvudine comparable to nirmatrelvir-ritonavir in ' 'real-world efficacy and safety for hospitalized patients with COVID-19? ' 'A retrospective cohort study. Infect Dis Therapy. 2023;12(8):2087–102. ' 'https://doi.org/10.1007/s40121-023-00845-7.', 'journal-title': 'Infect Dis Therapy'}, { 'key': '2220_CR21', 'doi-asserted-by': 'publisher', 'first-page': '1143485', 'DOI': '10.3389/fmed.2023.1143485', 'volume': '10', 'author': 'RM da Silva', 'year': '2023', 'unstructured': 'da Silva RM, et al. Serial viral load analysis by DDPCR to evaluate FNC ' 'efficacy and safety in the treatment of mild cases of COVID-19. Front ' 'Med. 2023;10:1143485. https://doi.org/10.3389/fmed.2023.1143485.', 'journal-title': 'Front Med'}, { 'issue': '4', 'key': '2220_CR22', 'doi-asserted-by': 'publisher', 'first-page': 'e28756', 'DOI': '10.1002/jmv.28756', 'volume': '95', 'author': 'G Deng', 'year': '2023', 'unstructured': 'Deng G, et al. Real-world effectiveness of Azvudine versus ' 'nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a ' 'retrospective cohort study. J Med Virol. 2023;95(4):e28756. ' 'https://doi.org/10.1002/jmv.28756.', 'journal-title': 'J Med Virol'}, { 'issue': '1', 'key': '2220_CR23', 'doi-asserted-by': 'publisher', 'first-page': '46', 'DOI': '10.1186/s12985-024-02316-y', 'volume': '21', 'author': 'Y Wang', 'year': '2024', 'unstructured': 'Wang Y, et al. Effectiveness of azvudine in reducing mortality of ' 'COVID-19 patients: a systematic review and meta-analysis. Virol J. ' '2024;21(1):46. https://doi.org/10.1186/s12985-024-02316-y.', 'journal-title': 'Virol J'}, { 'issue': '4', 'key': '2220_CR24', 'doi-asserted-by': 'publisher', 'first-page': '565', 'DOI': '10.1021/acs.accounts.1c00697', 'volume': '55', 'author': 'J Chang', 'year': '2022', 'unstructured': 'Chang J. 4’-modified nucleosides for antiviral drug discovery: ' 'achievements and perspectives. Acc Chem Res. 2022;55(4):565–78. ' 'https://doi.org/10.1021/acs.accounts.1c00697.', 'journal-title': 'Acc Chem Res'}, { 'key': '2220_CR25', 'doi-asserted-by': 'publisher', 'unstructured': 'Wang, Yaqi, et al. Efficacy and safety of azvudine for the treatment of ' 'COVID-19: a multicenter, open-label, randomized controlled trial. J ' 'Infect. 2021;83(3): 346–355. https://doi.org/10.1016/j.jinf.2021.05.008.', 'DOI': '10.1016/j.jinf.2021.05.008'}], 'container-title': 'European Journal of Medical Research', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s40001-024-02220-9.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s40001-024-02220-9/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s40001-024-02220-9.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 12, 26]], 'date-time': '2024-12-26T09:05:31Z', 'timestamp': 1735203931000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-024-02220-9'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 12, 26]]}, 'references-count': 25, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2024, 12]]}}, 'alternative-id': ['2220'], 'URL': 'http://dx.doi.org/10.1186/s40001-024-02220-9', 'relation': {}, 'ISSN': ['2047-783X'], 'subject': [], 'container-title-short': 'Eur J Med Res', 'published': {'date-parts': [[2024, 12, 26]]}, 'assertion': [ { 'value': '24 March 2024', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '14 December 2024', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '26 December 2024', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'There was no direct patient involvement in the conception, design, or ' 'implementation of this study. The requirement for patient consent was waived ' 'for this retrospective study, which utilized data from electronic medical ' 'records. This study was approved by the Ethics Committee of the First ' 'Affiliated Hospital of the Gannan Medical University Hospital (LLSL-2024065).', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval and consent to participate'}}, { 'value': 'Not applicable.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for publication'}}, { 'value': 'The authors declare no competing interests.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '625'}